Urovant Sciences Competitors

IGM Biosciences (NASDAQ:IGMS) and Urovant Sciences (NASDAQ:UROV) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Risk and Volatility

IGM Biosciences has a beta of -1.12, meaning that its share price is 212% less volatile than the S&P 500. Comparatively, Urovant Sciences has a beta of 2.36, meaning that its share price is 136% more volatile than the S&P 500.

Earnings and Valuation

This table compares IGM Biosciences and Urovant Sciences' gross revenue, earnings per share (EPS) and valuation.

IGM Biosciences is trading at a lower price-to-earnings ratio than Urovant Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares IGM Biosciences and Urovant Sciences' net margins, return on equity and return on assets.

Institutional & Insider Ownership

47.6% of IGM Biosciences shares are owned by institutional investors. Comparatively, 18.4% of Urovant Sciences shares are owned by institutional investors. 79.3% of IGM Biosciences shares are owned by company insiders. Comparatively, 2.7% of Urovant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for IGM Biosciences and Urovant Sciences, as provided by MarketBeat.com.

IGM Biosciences currently has a consensus target price of $98.8750, suggesting a potential upside of 44.36%. Urovant Sciences has a consensus target price of $16.1667, suggesting a potential downside of 0.45%. Given IGM Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe IGM Biosciences is more favorable than Urovant Sciences.

Summary

IGM Biosciences beats Urovant Sciences on 7 of the 11 factors compared between the two stocks.

Revance Therapeutics (NASDAQ:RVNC) and Urovant Sciences (NASDAQ:UROV) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Risk and Volatility

Revance Therapeutics has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500. Comparatively, Urovant Sciences has a beta of 2.36, meaning that its share price is 136% more volatile than the S&P 500.

Earnings and Valuation

This table compares Revance Therapeutics and Urovant Sciences' gross revenue, earnings per share (EPS) and valuation.

Urovant Sciences has lower revenue, but higher earnings than Revance Therapeutics. Revance Therapeutics is trading at a lower price-to-earnings ratio than Urovant Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Revance Therapeutics and Urovant Sciences' net margins, return on equity and return on assets.

Institutional & Insider Ownership

74.4% of Revance Therapeutics shares are owned by institutional investors. Comparatively, 18.4% of Urovant Sciences shares are owned by institutional investors. 4.8% of Revance Therapeutics shares are owned by company insiders. Comparatively, 2.7% of Urovant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Revance Therapeutics and Urovant Sciences, as provided by MarketBeat.com.

Revance Therapeutics currently has a consensus target price of $36.40, suggesting a potential upside of 29.40%. Urovant Sciences has a consensus target price of $16.1667, suggesting a potential downside of 0.45%. Given Revance Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Revance Therapeutics is more favorable than Urovant Sciences.

Summary

Revance Therapeutics beats Urovant Sciences on 8 of the 13 factors compared between the two stocks.

Dicerna Pharmaceuticals (NASDAQ:DRNA) and Urovant Sciences (NASDAQ:UROV) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Risk and Volatility

Dicerna Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Urovant Sciences has a beta of 2.36, meaning that its share price is 136% more volatile than the S&P 500.

Earnings and Valuation

This table compares Dicerna Pharmaceuticals and Urovant Sciences' gross revenue, earnings per share (EPS) and valuation.

Dicerna Pharmaceuticals has higher revenue and earnings than Urovant Sciences. Dicerna Pharmaceuticals is trading at a lower price-to-earnings ratio than Urovant Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Dicerna Pharmaceuticals and Urovant Sciences' net margins, return on equity and return on assets.

Institutional & Insider Ownership

80.6% of Dicerna Pharmaceuticals shares are owned by institutional investors. Comparatively, 18.4% of Urovant Sciences shares are owned by institutional investors. 11.3% of Dicerna Pharmaceuticals shares are owned by company insiders. Comparatively, 2.7% of Urovant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Dicerna Pharmaceuticals and Urovant Sciences, as provided by MarketBeat.com.

Dicerna Pharmaceuticals currently has a consensus target price of $37.8333, suggesting a potential upside of 45.01%. Urovant Sciences has a consensus target price of $16.1667, suggesting a potential downside of 0.45%. Given Dicerna Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Dicerna Pharmaceuticals is more favorable than Urovant Sciences.

Summary

Dicerna Pharmaceuticals beats Urovant Sciences on 9 of the 13 factors compared between the two stocks.

Axsome Therapeutics (NASDAQ:AXSM) and Urovant Sciences (NASDAQ:UROV) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Institutional & Insider Ownership

63.6% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 18.4% of Urovant Sciences shares are owned by institutional investors. 26.0% of Axsome Therapeutics shares are owned by company insiders. Comparatively, 2.7% of Urovant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Axsome Therapeutics has a beta of 2.59, meaning that its share price is 159% more volatile than the S&P 500. Comparatively, Urovant Sciences has a beta of 2.36, meaning that its share price is 136% more volatile than the S&P 500.

Profitability

This table compares Axsome Therapeutics and Urovant Sciences' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Axsome Therapeutics and Urovant Sciences, as provided by MarketBeat.com.

Axsome Therapeutics currently has a consensus target price of $146.90, suggesting a potential upside of 177.22%. Urovant Sciences has a consensus target price of $16.1667, suggesting a potential downside of 0.45%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Axsome Therapeutics is more favorable than Urovant Sciences.

Earnings and Valuation

This table compares Axsome Therapeutics and Urovant Sciences' gross revenue, earnings per share (EPS) and valuation.

Axsome Therapeutics is trading at a lower price-to-earnings ratio than Urovant Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Axsome Therapeutics beats Urovant Sciences on 9 of the 11 factors compared between the two stocks.

Urovant Sciences (NASDAQ:UROV) and NGM Biopharmaceuticals (NASDAQ:NGM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

Insider and Institutional Ownership

18.4% of Urovant Sciences shares are owned by institutional investors. Comparatively, 49.6% of NGM Biopharmaceuticals shares are owned by institutional investors. 2.7% of Urovant Sciences shares are owned by insiders. Comparatively, 50.4% of NGM Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Urovant Sciences has a beta of 2.36, indicating that its share price is 136% more volatile than the S&P 500. Comparatively, NGM Biopharmaceuticals has a beta of 1.97, indicating that its share price is 97% more volatile than the S&P 500.

Profitability

This table compares Urovant Sciences and NGM Biopharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations for Urovant Sciences and NGM Biopharmaceuticals, as reported by MarketBeat.

Urovant Sciences presently has a consensus price target of $16.1667, suggesting a potential downside of 0.45%. NGM Biopharmaceuticals has a consensus price target of $39.1111, suggesting a potential upside of 53.80%. Given NGM Biopharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe NGM Biopharmaceuticals is more favorable than Urovant Sciences.

Earnings & Valuation

This table compares Urovant Sciences and NGM Biopharmaceuticals' revenue, earnings per share (EPS) and valuation.

NGM Biopharmaceuticals has higher revenue and earnings than Urovant Sciences. NGM Biopharmaceuticals is trading at a lower price-to-earnings ratio than Urovant Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

NGM Biopharmaceuticals beats Urovant Sciences on 10 of the 14 factors compared between the two stocks.

Urovant Sciences (NASDAQ:UROV) and Morphic (NASDAQ:MORF) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

Insider and Institutional Ownership

18.4% of Urovant Sciences shares are owned by institutional investors. Comparatively, 61.5% of Morphic shares are owned by institutional investors. 2.7% of Urovant Sciences shares are owned by insiders. Comparatively, 39.5% of Morphic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Urovant Sciences has a beta of 2.36, indicating that its share price is 136% more volatile than the S&P 500. Comparatively, Morphic has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500.

Profitability

This table compares Urovant Sciences and Morphic's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations for Urovant Sciences and Morphic, as reported by MarketBeat.

Urovant Sciences presently has a consensus price target of $16.1667, suggesting a potential downside of 0.45%. Morphic has a consensus price target of $63.3333, suggesting a potential upside of 6.71%. Given Morphic's stronger consensus rating and higher probable upside, analysts plainly believe Morphic is more favorable than Urovant Sciences.

Earnings & Valuation

This table compares Urovant Sciences and Morphic's revenue, earnings per share (EPS) and valuation.

Morphic has higher revenue and earnings than Urovant Sciences. Morphic is trading at a lower price-to-earnings ratio than Urovant Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Morphic beats Urovant Sciences on 9 of the 12 factors compared between the two stocks.